Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ly-2874455. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 known ✓ | P22455 | 13/20 | 1.00 |
| ▸ | FGFR1 known ✓ | P11362 | 6/20 | 1.00 |
| ▸ | FGFR2 known ✓ | P21802 | 4/20 | 1.00 |
| ▸ | FGFR3 known ✓ | P22607 | 3/20 | 1.00 |
| ▸ | KDR | P35968 | 4/20 | 1.00 |
| ▸ | ETV6 | P41212 | 3/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ly-2874455 SCHEMBL297689 | 1.00 | FGFR4 (1.00) | FGFR4FGFR1FGFR2KDRFGFR3 | |
| Ly-2874455 SCHEMBL29627000 | 1.00 | FGFR4 (1.00) | FGFR4FGFR1FGFR2KDRFGFR3 | |
| Ly-2874455 SCHEMBL298446 | 1.00 | FGFR4 (1.00) | FGFR4FGFR1FGFR2KDRFGFR3 | |
| Ly-2874455 SCHEMBL297690 | 1.00 | FGFR4 (1.00) | FGFR4FGFR1FGFR2KDRFGFR3 | |
| Ly-2874455 SCHEMBL891768 | 0.99 | FGFR4 (0.98) | FGFR4FGFR1FGFR2KDRFGFR3 | |
| Ly-2874455 SCHEMBL891769 | 0.99 | FGFR4 (0.98) | FGFR4FGFR1FGFR2KDRFGFR3 | |
| Ly-2874455 SCHEMBL891766 | 0.99 | FGFR4 (0.98) | FGFR4FGFR1FGFR2KDRFGFR3 | |
| Ly-2874455 SCHEMBL891767 | 0.99 | FGFR4 (0.98) | FGFR4FGFR1FGFR2KDRFGFR3 | |
| SCHEMBL19821102 | 0.92 | FGFR4 (0.86) | FGFR4FGFR1FGFR2KDRFGFR3 | |
| SCHEMBL16921051 | 0.92 | FGFR4 (0.86) | FGFR4FGFR1FGFR2KDRFGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3957329-B1 | COMPOSITION COMPRISING THE COMBINATION OF SOTAGLIFLOZIN AS THE SODIUM/GLUCOSE CO-TRANSPORTER 1 INHIBITOR (SGLT1) AND A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 INHIBITOR (VEGFR2) FOR USE IN TREATING CANCER | NEWISH TECH BEIJING CO LTD (CN) | 2025-11-19 | — | — | EP | claimed |
| EP-3957310-B1 | COMPOSITION COMPRISING SOTAGLIFLOZIN AND A TYROSINE KINASE ACTIVITY INHIBITOR FOR USE IN THE TREATMENT OF CANCER | NEWISH TECH BEIJING CO LTD (CN) | 2025-05-21 | — | — | EP | claimed |
| EP-4412621-A2 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT Bio Corp. (US) | 2024-08-14 | — | — | EP | claimed |
| CN-117653737-A | Composition, application and medicine thereof | 诺未科技（北京）有限公司 | 2024-03-08 | — | — | CN | claimed |
| CN-117599188-A | Composition and application thereof in preparation of medicines for treating cancers | 诺未科技（北京）有限公司 | 2024-02-27 | — | — | CN | claimed |
| CN-117122596-A | Use of pan-FGFR inhibitors for modulating inflammatory responses | 四川大学 | 2023-11-28 | — | — | CN | claimed |
| CN-117018204-A | Composition for treating cancer and application and medicine thereof | 诺未科技（北京）有限公司 | 2023-11-10 | — | — | CN | claimed |
| WO-2023056202-A2 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT BIO CORP. (US) | 2023-04-06 | — | — | WO | claimed |
| CN-114569728-A | Composition, application thereof and medicine | 诺未科技（北京）有限公司 | 2022-06-03 | — | — | CN | claimed |
| EP-3964217-A1 | USE OF COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT, DIMER OR TRIMER THEREOF IN PREPARATION OF DRUG FOR TREATING CANCER | Newish Technology (Beijing) Co., Ltd. (CN) | 2022-03-09 | — | — | EP | claimed |
| EP-3957310-A1 | COMPOSITION AND USE THEREOF IN PREPARATION OF MEDICATION FOR TREATING CANCER | Newish Technology (Beijing) Co., Ltd. (CN) | 2022-02-23 | — | — | EP | claimed |
| EP-2427449-B1 | VINYL INDAZOLYL COMPOUNDS | LILLY CO ELI (US) | 2013-04-03 | — | — | EP | claimed |
| US-8268869-B2 | Vinyl indazolyl compounds | ELI LILLY AND COMPANY (US) | 2012-09-18 | — | — | US | claimed |
| US-20120083511-A1 | CRYSTALLINE (R)-(E)-2-(4-(2-(5-(1-(3,5-DICHLOROPYRIDIN-4-YL)ETHOXY)-1H-INDAZOL-3-YL)VINYL)-1H-PYRAZOL-1-YL)ETHANOL | ELI LILLY AND COMPANY (US) | 2012-04-05 | — | — | US | claimed |
| EP-2427449-A1 | VINYL INDAZOLYL COMPOUNDS | Eli Lilly and Company (US) | 2012-03-14 | — | — | EP | claimed |
| WO-2010129509-A1 | VINYL INDAZOLYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2010-11-11 | — | — | WO | claimed |
| US-20100286209-A1 | VINYL INDAZOLYL COMPOUNDS | ELI LILLY AND COMPANY | 2010-11-11 | — | — | US | claimed |
| EP-3954436-B1 | METHOD FOR PRODUCING BIOTISSUE-LIKE STRUCTURE | ORIZURU THERAPEUTICS INC (JP) | 2026-01-07 | — | — | EP | disclosed |
| WO-2010129509-A1 | VINYL INDAZOLYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129509-A1 | VINYL INDAZOLYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083511-A1 | CRYSTALLINE (R)-(E)-2-(4-(2-(5-(1-(3,5-DICHLOROPYRIDIN-4-YL)ETHOXY)-1H-INDAZOL-3-YL)VINYL)-1H-PYRAZOL-1-YL)ETHANOL | ADH1A, ADH1C, ADH5 | FGFR4 361/4885FGFR1 112/4885FGFR2 139/4885 |
| US-20100286209-A1 | VINYL INDAZOLYL COMPOUNDS | VHL, IDH3B, IDH3A | FGFR4 67/4885FGFR1 322/4885FGFR2 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.